doi: 10.1016/j.tem.2023.03.002 150 KnightRWalkerVIpSCooperJBoltonTKeeneSet al
has received consulting fees from Akero, Alentis, Alexion, Altimmune, Astra Zeneca, 89Bio, Bionorica, Boehringer Ingelheim, Gilead Sciences, GSK, HistoIndex, Ipsen, Inventiva Pharma, Madrigal Pharmaceuticals, Krya Therapeutics, Lilly, MSD Sharp & Dohme GmbH, Nordic Bioscience, Northsea Therapeutics, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi, Siemens Healthineers, Summit Clinical, Vantage Biosciences Research, and Worldwide Clinical Trials
High Purity: Typically 95%, confirmed through chromatographic and spectrometric methods
Genetic factors influencing glucagon-like peptide-1 receptor sensitivity and glucose metabolism may affect both tolerability and therapeutic benefit over time
The study says GLP-1 medications interact with reward pathways in the brain, which are involved in addiction
However, substantial evidence exists for related medications and the broader concept of pharmaceutical augmentation after surgery